Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigimadlin Monotherapy in MDM2-Amplified TP53 Wild-Type Solid Tumors
CTR20233213Phase 2Terminated
- Sponsor
- Not applicable
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brigimadlin in cholangiocarcinoma (CCA), pancreatic adenocarcinoma (PDAC), Non-small cell lung cancer adenocarcinoma (NSCLC), transitional cell carcinoma of the bladder (TCC), Nonhematologic neoplasms, sponsored by Not applicable. Started Nov 2023; status: terminated.
02
Drugs
brigimadlin
03
Conditions
cholangiocarcinoma (CCA)pancreatic adenocarcinoma (PDAC)Non-small cell lung cancer adenocarcinoma (NSCLC)transitional cell carcinoma of the bladder (TCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20233213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233213.